Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.64 |
| ▸ | HTR2B | P41595 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | USP2 | O75604 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | CHRM5 | P08912 | 6/20 | 0.51 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | STAT3 | P40763 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30456888 | 1.00 | KMT2A (0.64) | KMT2AHTR2BALDH1A1LMNAUSP2 | |
| SCHEMBL25723501 | 0.88 | KMT2A (0.58) | KMT2AHTR2BALDH1A1LMNAUSP2 | |
| SCHEMBL28181531 | 0.81 | KMT2A (0.72) | KMT2AHTR2BALDH1A1LMNAUSP2 | |
| SCHEMBL20456469 | 0.80 | HTR2B (0.86) | KMT2AHTR2BALDH1A1LMNAUSP2 | |
| SCHEMBL20456414 | 0.80 | KMT2A (0.78) | KMT2AHTR2BALDH1A1LMNAUSP2 | |
| SCHEMBL20456209 | 0.78 | KMT2A (1.00) | KMT2AHTR2BALDH1A1LMNAUSP2 | |
| SCHEMBL1299053 | 0.78 | HTR2B (1.00) | KMT2AHTR2BALDH1A1LMNAUSP2 | |
| SCHEMBL20456427 | 0.76 | KMT2A (0.74) | KMT2AHTR2BALDH1A1LMNAUSP2 | |
| SCHEMBL20456208 | 0.76 | KMT2A (0.74) | KMT2AHTR2BALDH1A1LMNAUSP2 | |
| SCHEMBL20456447 | 0.76 | HTR2B (0.78) | KMT2AHTR2BALDH1A1LMNAUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183237-A1 | COMPETITIVE AND NONCOMPETITIVE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 | VANDERBILT UNIVERSITY | 2023-06-15 | — | — | US | disclosed |
| US-20230183237-A1 | COMPETITIVE AND NONCOMPETITIVE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 | VANDERBILT UNIVERSITY | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183237-A1 | COMPETITIVE AND NONCOMPETITIVE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 | CHRM5, CHRM1, CHRM2 | KMT2A 1139/4885HTR2B 54/4885ALDH1A1 622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.